Alterity Therapeutics Ltd ADR (ATHE) Stock Price, Quote & News

Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9349 4906

Fax: 61 3 9349 4906

Website: alteritytherapeutics.com

Address:

350 Collins Street, Suite 4 Level 14, Melbourne, Australia

stckmuncher Oct. 25 at 1:11 AM

$ATHE Literally on a plane from DFW to DTW as we speak and folks sitting behind me are talking ATHE. Big things coming!

0 · Reply

stckmuncher Oct. 25 at 1:09 AM

$ATHE 🚀

0 · Reply

stckmuncher Oct. 25 at 1:09 AM

$ATHE 🤠

0 · Reply

stckmuncher Oct. 25 at 1:09 AM

$ATHE 😀

0 · Reply

My_Lai_1968 Oct. 24 at 5:36 AM

$ATHE I was totally confined to a hospital for the first 7 years of my life after accidentally swallowing a harmonica (most likely before I was one year old). Nobody knew until I began coughing badly and a slew of melodies loudly resonated in my throat. I still vividly recall the radiologist telling a nurse that "ATHE is a garbage stock". I'm not sure exactly why he thought that but I did see them both walk to the cafeteria together.

1 · Reply

Botmax Oct. 22 at 11:55 PM

$ATHE Ok I have commented on a couple of posts but time to put this Resolution 7 to rest. See below this is from the AGM notice only recently of another Australian biotech DXB. I have been trading investing on the ASX for over 15 years. I am yet to see a single AGM notice in my time for a small cap that doesn't have this resolution. Literally copy and paste for all of them. Doesn't mean they will use it. Its like having a credit card that you don't necessarily need but its nice to have in the back pocket in case of emergency. That's all it is nothing to explain.

4 · Reply

GA09 Oct. 22 at 7:24 PM

$ATHE CEO will need to explain Resolution 7 because it is confusing. CEO stated he did not favor a dilution but instead would focus on identifying a strategic partner (or a buy-out). So Resolution 7 is confusing and concerning.

2 · Reply

motherlandreturns Oct. 22 at 12:51 PM

$ATHE so is this common when trying to find a partner or acquirer? Does this mean they can issue 10% more stock contributing to dilution?

1 · Reply

chrikub Oct. 22 at 12:38 AM

$ATHE https://www.neurologylive.com/view/multiple-system-atrophy-phase-2-findings-reinforce-ath434-disease-modifying-potential

0 · Reply

Double__Down Oct. 22 at 12:31 AM

$ATHE are we being diluted again?

2 · Reply

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Oct 2, 2025, 7:35 AM EDT - 23 days ago

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Sep 8, 2025, 7:35 AM EDT - 6 weeks ago

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Sep 2, 2025, 7:25 AM EDT - 7 weeks ago

Alterity Therapeutics to Present at the Biotech Showcase

Jul 30, 2025, 7:25 AM EDT - 3 months ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Jul 28, 2025, 7:25 AM EDT - 3 months ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Jul 24, 2025, 7:25 AM EDT - 3 months ago

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Jun 23, 2025, 7:25 AM EDT - 4 months ago

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

May 12, 2025, 7:35 AM EDT - 5 months ago

Alterity Therapeutics Prominently Featured at the International MSA Congress

May 7, 2025, 8:16 AM EDT - 6 months ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 5, 2025, 7:35 AM EDT - 6 months ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Apr 30, 2025, 7:35 AM EDT - 6 months ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 28, 2025, 7:35 AM EDT - 6 months ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Apr 10, 2025, 7:35 AM EDT - 7 months ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Mar 27, 2025, 7:25 AM EDT - 7 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Feb 10, 2025, 7:25 AM EST - 9 months ago

Alterity Therapeutics Raises A$40.0 million in Placement

Jan 30, 2025, 7:35 AM EST - 9 months ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Jan 24, 2025, 7:35 AM EST - 9 months ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 9, 2025, 7:25 AM EST - 10 months ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Dec 4, 2024, 7:35 AM EST - 11 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Nov 19, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 12, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Nov 6, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Oct 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 14, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Oct 11, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 2, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 30, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 23, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 24, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Present at MST Financial Webinar

Jul 17, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jun 12, 2024, 7:22 PM EDT - 1 year ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

May 29, 2024, 7:21 PM EDT - 1 year ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 8, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Apr 30, 2024, 7:25 AM EDT - 1 year ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 29, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Apr 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 10, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Mar 26, 2024, 10:25 AM EDT - 1 year ago

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Feb 20, 2024, 10:25 AM EST - 1 year ago

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Feb 6, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Jan 29, 2024, 7:24 AM EST - 1 year ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Dec 21, 2023, 12:30 AM EST - 2 years ago

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Dec 4, 2023, 4:35 PM EST - 2 years ago

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Dec 4, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Nov 27, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Nov 16, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

Nov 8, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

stckmuncher Oct. 25 at 1:11 AM

$ATHE Literally on a plane from DFW to DTW as we speak and folks sitting behind me are talking ATHE. Big things coming!

0 · Reply

stckmuncher Oct. 25 at 1:09 AM

$ATHE 🚀

0 · Reply

stckmuncher Oct. 25 at 1:09 AM

$ATHE 🤠

0 · Reply

stckmuncher Oct. 25 at 1:09 AM

$ATHE 😀

0 · Reply

My_Lai_1968 Oct. 24 at 5:36 AM

1 · Reply

Botmax Oct. 22 at 11:55 PM

4 · Reply

GA09 Oct. 22 at 7:24 PM

2 · Reply

motherlandreturns Oct. 22 at 12:51 PM

$ATHE so is this common when trying to find a partner or acquirer? Does this mean they can issue 10% more stock contributing to dilution?

1 · Reply

chrikub Oct. 22 at 12:38 AM

$ATHE https://www.neurologylive.com/view/multiple-system-atrophy-phase-2-findings-reinforce-ath434-disease-modifying-potential

0 · Reply

Double__Down Oct. 22 at 12:31 AM

$ATHE are we being diluted again?

2 · Reply

GA09 Oct. 21 at 9:39 PM

$ATHE Interesting clause, "any proportional takeover bids"...

1 · Reply

yft212 Oct. 21 at 3:29 PM

$GLSI $ATHE $MNKD $SNWV $MLTX Maybe we some mergers or buyouts this year. https://www.fiercepharma.com/manufacturing/merck-grows-again-virginia-3b-small-molecule-drug-plant-500-hires

0 · Reply

Nimmer1 Oct. 21 at 8:20 AM

$ATHE Today Alterithy announced their agenda for their General annual meeting. Interesting enough, they have a long proposal regarding the handling of a coming take over and how that should be handled ?? Why would you prepare for that ?🙂

1 · Reply

DrevanTheStillblade Oct. 19 at 4:23 PM

Watch VRME possible super run incoming VRME has a rare “floor + optional upside” setup. Strong cash reserves, improving cash flow, tight structure and a golden cross brewing. When volume steps in, this could stretch beyond typical penny stock ranges. $GLMD $ATHE $ACHL $CRVS

1 · Reply

BrokersNY Oct. 17 at 12:54 PM

$ATHE get ready for a flight soon

0 · Reply

Double__Down Oct. 17 at 3:12 AM

$ATHE slowly continue to accumulate at these levels. Any thoughts on what the floor is here? Will there be another pull back or only up from here?

3 · Reply

stckmuncher Oct. 16 at 11:41 PM

$ATHE Why would you not accumulate here? Folks still selling like crazy…

0 · Reply

DegenWizard Oct. 16 at 3:36 PM

$ATHE still slowly climbing. Large purchases at market price driving a slow up trend. Extremely low volume. Minimal sales. Pretty cool to see.

1 · Reply

stckmuncher Oct. 16 at 12:53 AM

$ATHE YE PEAK PRICE PREDICTION??? I will go first…$367 a share.

2 · Reply

stckmuncher Oct. 16 at 12:43 AM

$ATHE BUY AND HOLD FOLKS…

0 · Reply

jOm_50Root Oct. 15 at 5:51 PM

$ATHE PT anchoring is a psychological cheat code. Print 14 often enough and risk desks reference it. With spot sub 2, R R screens asymmetric. A one unit risk to prior swing low can target 3 to 4 units toward 3.5 then 5. Execution is about phases, not hero entries. 💎

0 · Reply

motherlandreturns Oct. 15 at 4:55 PM

$ATHE Should have bought more when this broke below 4 a few weeks back,

0 · Reply

Market Cap	40.79M
Revenue (ttm)	0.00
Net Income (ttm)	-7.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	14,800
Avg Vol	107,976
Day's Range	N/A - N/A
Shares Out	8.87M
Stochastic %K	13%
Beta	0.30
Analysts	Strong Sell
Price Target	$11.00